Navigation Links
Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
Date:3/12/2008

WOBURN, Massachusetts, March 12 /PRNewswire/ -- Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has signed an exclusive license agreement with Makoto Life Sciences, Inc., of Cambridge, Massachusetts.

Under this agreement, MTI has licensed to Makoto its lead series of high potency activators of AMP-activated protein kinase (AMPK), a well validated drug target for the treatment of Type-2 diabetes. As part of the license, MTI will transfer all assets related to its MT-39 series of indirect AMPK activators, including all materials, research notes, synthetic routes, and the structures of over 40 compounds. MTI will advise Makoto on the continuing development of the MT-39 series.

Unlike MTI's internal R&D program, which is focused on developing small molecules that activate AMPK by direct binding, the MT-39 series of compounds are indirect AMPK activators and appear to act with high potency through a cellular pathway which has not yet been identified. The successful clarification of this pathway may lead to the development of new targets and compounds for the treatment of metabolic disease.

MTI's series of compounds were originally identified in the course of a collaboration with Aventis, a large pharmaceutical company. That relationship ended in 2004 and all rights, including the MT-39 series of compounds, reverted entirely and exclusively to Mercury. MTI subsequently launched a medicinal chemistry program targeting the MT-39 core structure, and identified a number of congeners with low nanomolar activities and efficacy in animal models of glucose metabolism. As activators of AMPK, the MT-39 series of compounds could be expected to improve glycemic control in Type-2 diabetics, and lower other risk factors associated with cardiovascular disease.

While the specific terms of the license agreement have not been disclosed, Makoto will be responsible, among
'/>"/>

SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
2. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
3. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
4. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
5. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
6. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
7. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
8. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO CEO & Investor Conference
9. Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
10. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
11. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , ST. LOUIS, Nov. 24 /PRNewswire-FirstCall/...l be presenting at the NASDAQ OMX conference on Tu... AM US/CST. Interested parties may listen via live...http://inve s tor.sig m a a ldrich.com/ . ...file. ,, About Sigma-Aldrich: Sigma-Aldri...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/...ood & Drug Administration (SFDA) has approved ... its oral insulin project,(Nodlin), an innovative ...proval allows Biolaxy to initiate its first phase ...r characteristic of high blood glucose and poor,me...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-FirstCa...global specialty biopharmaceutical company, today,...ean Medicines Agency for,velaglucerase alfa, the c...,for the treatment of Type 1 Gaucher disease. This...ase alfa that has been submitted, with previous,su...
(Date:11/24/2009)... Chemical Abstracts Service (CA...orts that China,s patent office is now the world,s... in chemistry. China trailed Japan,s patent office...PO), and the United States Patent and Trademark Of...e USPTO in 2005, WIPO in 2006, and exceeded Japan ...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
... GE Healthcare , a unit of General Electric Comp..., miniaturized cardiovascular ultrasound that is e...The new visual stethoscope, Vivid i, is designed t...n a portable and wireless design that weighs 30 ti...s to receive diagnostic exams anywhere, including ...
... One day back in 1992, someone telephoned Dr. Kel...and Microbiology at the Medical College of Wiscon...l. of fluid with a monoclonal antibody in it. , ,H...stomer was happy to have found a way to purchase m...ians were clamoring for," Henrickson explained. Th...
... ,Rebecca Ryan MILWAUKEE - Watts Wacker, hippie ex...Young Professionals of Milwaukee,s third birthday ...had to borrow a pen to take notes. Here,s what Wat..., ,Watts: When Jesus Christ died, there were 200 C...aid down, there were 200,000 Christians. Guess Pau...
Other Biology Technology:GE Healthcare announces new, high-tech 'stethoscope' 2Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc. 2Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc. 3Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc. 4Watts Up 2
(Date:11/23/2009).... November 23, 2009 Applied mathematicians disse...ancifolia ), a characteristic long leaf with a sad... along the edges. The simple cause of the lily,s f...ding during differential growthwas revealed by usi...bbons. , Haiyi Liang, a postdoctoral student at ...
(Date:11/23/2009)...e Wildlife Conservation Society says that western ...public of Congopart of the "mother lode" of more t...ing increasingly threatened by growing humans acti...ction of the swamp forests adjacent to the southwe... surveys confirmed that high densities of the grea...
(Date:11/23/2009)...rent research suggests that a common oral bacteriu...report by Nichols et al, "Unique Lipids from a Com...Ligands Capable of Enhancing Autoimmunity," appear...nal of Pathology . , Multiple sclerosis (MS), a ...and spinal cord, affects nearly 1 in 700 people in...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Factors from common human bacteria may trigger multiple sclerosis 2 243 5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 56648 1 243 5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 56648 2 243 5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 56648 3AGU journal highlights Sept 9 2009 9849 1AGU journal highlights Sept 9 2009 9849 2AGU journal highlights Sept 9 2009 9849 3AGU journal highlights Sept 9 2009 9849 4AGU journal highlights Sept 9 2009 9849 5AGU journal highlights Sept 9 2009 9849 6AGU journal highlights Sept 9 2009 9849 7AGU journal highlights Sept 9 2009 9849 8New Vaccine May Work Better Against Lung Disease 56647 1New Vaccine May Work Better Against Lung Disease 56647 2
...utions to the ancient problem of maintaining a fre... the Inderscience publication International Journa...ore than 3.5 billion people will live in areas fac...hallenge is to find an environmentally benign way ...ange, desertification, and over-population are alr...
...nt Bush announced on November 16 that the Ecologic...ts of the 2006 Presidential Award for Excellence i...PAESMEM). ESA is the only organization to receive...l individuals. The award, the highest of its kind...ed by the National Science Foundation (NSF) and in...
...a, CA and New Brunswick, NJ, November 19, 2007 Ra...into an innovative collaboration with Rutgers Univ...on (MTF), the nations largest tissue bank, to impr...n a first-of-its-kind test, world leading tissue e...d on the Raydiance Ultrashort Pulse (USP) laser pl...
Other Biology News:Nuclear desalination 2Nuclear desalination 3ESA honored at White House ceremony 2ESA honored at White House ceremony 3Raydiance collaborates with Rutgers, MTF to develop innovative tissue processing approaches 2
Anti-Transglutaminase II Monoclonal Antibody, Unconjugated, Clone CUB7402 from Diagnostic BioSystems
Marker for 2D Electrophoresis from Sigma-Aldrich
...HT robot is based on PI's experience in high-resol...than a decade. PI Hexapods were originally used in...justments over wide ranges in small step sizes. Th...inimum incremental motion (combined 6-axis move, d...
...a full length insert sequencing service for large ... Agencourt utilizes unique library construction te... are several features that allow Agencourt to prov...ound including our patented magnetic bead-based SP...
Biology Products: